Clinical trials: Malignant Ascites
Malignant Pleural Effusion, Malignant Ascites
A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites
Malignant pleural effusion and/ or malignant ascites is generally defined by presence of malignant cells in the effusion fluid. The first-line therapies are mostly intrusive, medically demanding and inefficient, and therefore, it…
- Trial name
- NCT03736122
- Testing
- BSG-001
- Where
- Australia
- Volunteers
- 58 people
- Sponsor
- BioSyngen Pte Ltd
Ovarian Neoplasms Malignant, Ascites
Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites
This is a single-center, open-label, Phase I/II clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of SK-NK Cell Injection administered via intraperitoneal (IP) perfusion in patients with…
- Trial name
- NCT07435701
- Testing
- SK-NK Cell Injection
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Malignant Ascites
Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites
This study makes an observation over the objective response rate of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination in the treatment of malignant…
- Trial name
- NCT03230708
- Testing
- Erythrocytes derived MPs containing MTX, convention drugs
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hui ting Xu，MD
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
This phase II trial is studying how well EF5 works in detecting oxygen level and blood vessels in tumor cells of patients who are undergoing photodynamic therapy for intraperitoneal or pleural cancer.
- Conditions
- Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Malignant Ascites, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00028782
- Testing
- etanidazole, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Ascites
Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody
A Phase II, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of M701 in treating Patients with Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer combined with Systemic Therapy.
- Trial name
- NCT06266091
- Testing
- M701, paracentesis
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Malignant Ascites
EUS-Guided Drainage of Refractory Malignant Ascites
This study evaluates the efficacy and safety of drainage of refractory malignant ascites by endoscopic ultrasound-guided (EUS-Guided) implantation of plastic prostheses.
- Trial name
- NCT03550560
- Testing
- EUS-Guided drainage
- Volunteers
- 100 people
- Sponsor
- Hospital Universitario Virgen Macarena
Malignant Ascites
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody
A Randomized, Controlled, Multi-Center Phase III Clinical Study to Compare the Efficacy and Safety of Recombinant Anti-EpCAM and Anti-CD3 Human-Mouse Chimeric Bispecific Antibody (M701) for Intraperitoneal Injection to…
- Trial name
- NCT06432296
- Testing
- M701, paracentesis
- Where
- 2 sites in China
- Volunteers
- 312 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Refractory Malignant Ascites
Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites
Assessment of effectiveness, safety and local immune activation of Oncolytic Viruses H101 in patients with refractory malignant ascites.
- Trial name
- NCT04771676
- Testing
- Oncorine (H101)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Malignant Ascites
Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites
This study will evaluate the safety and efficacy of intraperitoneal administration of Bevacizumab to prevent the recurrence of malignant ascites.
- Trial name
- NCT02496286
- Testing
- Intraperitoneal Bevacizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eastern Regional Medical Center